For this, human acute erythroid leukemia HEL cells, which naturally harbor the JAK2 V617F mutation homozygously, were treated for 4 h with DMSO or ruxolitinib and then incubated with and without the antimitotic drug NMS-P715 (MPS1i) to induce SAC malfunction. This evidence concerns the gene JAK2 and acute erythroid leukemia.